Metabolomics is the identification and quantification of the complete set of metabolites in a biological system. The steps involved in metabolomics analysis are profiling, identification, quantification, and interpretation. Profiling is finding all the metabolites detectable to a selected analytical technique with the significant variations in abundance with a set of experimental and control groups. Metabolomics applications are segmented into the following: Biomarker Discovery, Drug Discovery, Personalized Medicine, Nutrigenomics, and Toxicology. The Biomarker Discovery segment generated the highest revenue in 2016, mainly due to the advancements of biomarkers metabolic profiling and diagnostic proficiencies of metabolic biomarkers for disease management at the metabolic level. The Personalized Medicine segment is expected to witness the fastest growth during the forecast period due to increasing collaborations of pharmaceutical and biotech companies for biomarker discovery and validation.
Wide range of metabolomics application in R&D and therapeutic areas is expected to drive the market. Moreover, introduction of various separation techniques to enhance the process to identification and quantification of cellular metabolites is expected to be another major factor to drive the growth of the market during the forecast period. The markets in India, China, and Japan are also expected to grow at a rapid pace during the forecast period due to refining biopharmaceutical research infrastructure, huge population, and growing healthcare requirements.
The “Global Metabolomics Market” is estimated to witness a CAGR of 13.5% during the forecast period 2017–2023. The Metabolomics market is analyzed based on two segments – applications and regions.
The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (ROW). The Americas is set to be the leading region for the metabolomics market growth followed by Europe. The Asia Pacific and ROW are set to be the emerging regions. The exclusivity of metabolomics applications for the Chinese population has led to the demand of upcoming R&D investments from MNCs in the APAC region and is expected to offer competitive edge to local players.
Thermo Fisher Scientific Inc., Danaher Corp., Waters corp., Agilent Technologies Inc., Shimadzu Corp., Bruker Corp., Bio-Rad Laboratories Inc. and other predominate & niche players.
The Metabolomics market is defined by the big MNCs. The big players along with the collaboration with other SMBs for clinical trials and R&D investments, are coming with new applications in the market, which is expected to produce double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue during the forecast period.
The report provides complete details about the usage and adoption rate of metabolomics in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives towards the metabolomics adoption in the upcoming years along with the details of application areas available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.